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Abstract
Background: Estrogens exert anti-inflammatory and neuroprotective effects in the brain mainly via estrogen
receptors a (ERa) and b (ERb). These receptors are members of the nuclear receptor superfamily of ligand-
dependent transcription factors. This study was aimed at the elucidation of the effects of ERa and ERb agonists on
the expression of neuroinflammatory genes in the frontal cortex of aging female rats.
Methods: To identify estrogen-responsive immunity/inflammation genes, we treated middle-aged, ovariectomized
rats with 17b-estradiol (E2), ERa agonist 16a-lactone-estradiol (16a-LE2) and ERb agonist diarylpropionitrile (DPN),
or vehicle by Alzet minipump delivery for 29 days. Then we compared the transcriptomes of the frontal cortex of
estrogen-deprived versus ER agonist-treated animals using Affymetrix Rat230 2.0 expression arrays and TaqMan-
based quantitative real-time PCR. Microarray and PCR data were evaluated by using Bioconductor packages and
the RealTime StatMiner software, respectively.
Results: Microarray analysis revealed the transcriptional regulation of 21 immunity/inflammation genes by 16a-LE2.
The subsequent comparative real-time PCR study analyzed the isotype specific effects of ER agonists on
neuroinflammatory genes of primarily glial origin. E2 regulated the expression of sixteen genes, including down-
regulation of complement C3 and C4b, Ccl2, Tgfb1, macrophage expressed gene Mpeg1, RT1-Aw2, Cx3cr1, Fcgr2b,
Cd11b, Tlr4 and Tlr9, and up-regulation of defensin Np4 and RatNP-3b, IgG-2a, Il6 and ER gene Esr1. Similar to E2,
both 16a-LE2 and DPN evoked up-regulation of defensins, IgG-2a and Il6, and down-regulation of C3 and its
receptor Cd11b, Ccl2, RT1-Aw2 and Fcgr2b.
Conclusions: These findings provide evidence that E2, 16a-LE2 and DPN modulate the expression of
neuroinflammatory genes in the frontal cortex of middle-aged female rats via both ERa and ERb. We propose that
ERb is a promising target to suppress regulatory functions of glial cells in the E2-deprived female brain and in
various neuroinflammatory diseases.
Background
The complex interactions between the immune and cen-
tral nervous systems govern the innate immune
responses in the brain [1]. Microglial cells survey their
environment through continuous remodeling of cellular
processes [2]. These cells respond to injury or infection
and induce a variety of secondary responses including
activation of astrocytes [3] and migration of peripheral
immune cells into the brain [4,5]. The activation of glial
cells and recruitment of immune cells subserve the brain
homeostasis. Estrogens modulate the function of many
cell types of the immune [6] and the central nervous
systems [7,8]. In females, E2 levels drop abruptly at the
time of menopause resulting in a low grade of systemic
inflammation which can be prevented by chronic treat-
ment with low dose of E2 [9]. E2 modulates inflamma-
tory processes in models of human diseases such as
arthritis [10], systemic lupus erythematosus, Alzheimer
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any medium, provided the original work is properly cited.disease [11] and multiple sclerosis [12]. In the rat brain,
E2 suppresses activation of microglia, recruitment of
blood-derived monocytes, and expression of C3 receptor
and matrix metalloproteinase-9 after intracerebroventri-
cular injection of LPS [13]. E2 also inhibits the expression
of pro-inflammatory cytokines IL1b and TNFa in LPS-
treated primary astrocytes [14]. These studies indicate
that E2 may regulate both microglia and astrocyte func-
tions related to inflammation.
The effects of E2 are primarily mediated by ERa and
ERb which are members of the nuclear receptor super-
family of ligand-activated transcription factors [15]. ERa
and ERb regulate gene expression through multiple
mechanisms. Via a classic mode of action, ERs can
induce transcription upon binding to estrogen-respon-
sive elements in target gene promoters. They can also
modulate transcription via interfering with other promo-
ter-bound transcription factors, or via influencing a vari-
ety of intracellular signaling pathways [16]. In the frontal
cortex, E2 may alter gene transcription directly via ERs
in inhibitory interneurons [17], astrocytes [18] and
microglia [13,19]. However, the knowledge on estrogenic
regulation of neuroinflammatory genes is limited in the
cerebral cortex of middle-aged females. In a rodent
menopausal model, we have recently described changes
of the cortical transcriptome as a result of E2 replace-
m e n t[ 2 0 ] .W eh a v ei d e n t i f i e ds o m ei m m u n i t yg e n e s
encoding complement (C) proteins and MHC antigens
among the genes with the highest fold change. Down-
regulation of these genes is in line with the anti-inflam-
matory activity of E2 in neuroinflammatory disease
models [11-13].
To identify estrogen-responsive neuroinflammatory
genes in the frontal cortex of middle-aged female rats, we
compared the transcriptomes of ovariectomized and ERa
agonist-treated animals using oligonucleotide microarrays.
Based on the results of our microarray analysis and on the
knowledge regarding the expression profile of glial cells,
we selected a set of potential estrogen target genes of pri-
marily glial origin. Then we examined the transcription of
these genes involved in the recognition of danger- and
pathogen-associated signals, cellular defense, phagocytosis,
neuron-microglia communication and immune regulation
after chronic treatments with E2, ERa agonist 16a-LE2
[21] and ERb agonist DPN [22]. We demonstrated that
these ER agonists regulate the transcription of a large
number of neuroinflammatory genes in the frontal cortex
of middle-aged female rats.
Methods
Chemicals
3,17b-dihydroxy-19-nor-17a-pregna-1,3,5(10)-triene-
21,16a-lactone (16a-LE2) was originally designed,
synthesized and patented by Schering AG [23]. This
compound was re-synthesized in the Laboratory of Ster-
oid Chemistry at Gedeon Richter Plc. NMR spectra
(Varian NMR System 300) and melting points were
identical to published data [23]. E2 and DPN were
purchased from Sigma (St. Louis, MO) and Tocris (Ellis-
ville, MO), respectively.
Experimental animals and treatments
Female, middle-aged retired breeder Harlan-Wistar rats
were purchased from Toxicoop (Budapest, Hungary).
Animals were housed individually in the animal care
facility of Institute of Experimental Medicine (IEM) on a
12 h light/12 h dark cycle, and with unrestricted access
to phytoestrogen-free rodent diet (Harlan Teklad Global
Diets, Madison, WI) and tap water. At the age of 13
months, the rats were deeply anesthetized and ovariec-
tomized bilaterally. Ten days later, Alzet 2004 mini-
pumps (DURECT, Cupertino, CA) filled with 16a-LE2
(3,33 mg/ml in propylene-glycol, n = 6) and vehicle (n =
6, control group) were implanted subcutaneously for 29
days. Concentration of 16a-LE2 was calculated to pro-
duce a release rate of 20 μg/d [21]. For further replace-
ment experiments, Alzet 2004 minipumps were filled
either with E2 (0,333 mg/ml in propylene-glycol, n = 6)
or DPN (3,33 mg/ml in propylene-glycol, n = 6) and
were implanted for 29 days. Concentrations were calcu-
lated to produce a release rate of 2 μg/d and 20 μg/d,
respectively [21]. Body weight and uterus weight were
measured to follow the peripheral effects of the treat-
ments (Figure 1). For the preparation of the frontal cor-
tex the same protocol was followed as published earlier
[24]. Protocols were approved by the Animal Welfare
Committee of IEM (No.: A5769-01). Experiments were
carried out in accordance with the legal requirements of
the European Community (Decree 86/609/EEC).
Total RNA isolation from the cerebral cortex
Total RNA was isolated from the frontal cortex using
the RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden,
Germany). RNA analytics included A260 nm/A280 nm
readings using a Nanodrop Spectrophotometer and
capillary electrophoresis using Agilent 2100 Bioanalyzer
(Santa Clara, CA). All RNA samples displayed RNA
integrity numbers (RIN) above 8.2.
Expression profiling using Rat 230 2.0 Expression Arrays
One-cycle target labeling, hybridization, staining and
scanning were carried out as described earlier [24]. In
brief, preparation of poly-A RNA controls (spike-in con-
trols), first and second strand cDNA synthesis, cleanup,
in vitro transcription labeling, cleanup of biotin-labeled
cRNA and fragmentation were carried out according to
the Affymetrix technical manual. Fragmented cRNA was
hybridized for 16 h to Affymetrix Rat 230 2.0 Expression
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stained with phycoerythrin-conjugated streptavidin
(Molecular Probes, Eugene, OR). Fluorescence intensi-
ties were determined using the GCS 3000 confocal laser
scanner (Affymetrix). Scanned images were analyzed
using programs resident in GeneChip
® Operating Sys-
tem v1.2 (GCOS Affymetrix).
Data analysis
For data analysis, we followed the same protocol as before
[20]. In brief, for quality control we used the affyQCReport
package. Raw microarray data were pre-processed for ana-
lysis by GCRMA [25]. After outlier identification [26], lin-
ear models combined with empirical Bayesian methods
were applied [27] and the raw fold change values were
used to select differentially expressed genes [28]. P-values
were adjusted by the FDR-based method [29]. In gene set
enrichment analysis, KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways [30] were used as collaborator
gene sets, analyzed by a recently developed method [31].
In all statistical and data mining work Bioconductor
packages [32] in R-environment [33] were used.
Quantitative real-time PCR
Custom TaqMan low density arrays (TLDA) were
designed to confirm microarray results and to study in
depth the regulation of microglia-related genes by quanti-
tative real-time PCR. Microfluidic cards (Applied
Biosystems, Santa Clara, CA) were preloaded by the man-
ufacturer with selected inventoried assays for the genes of
our interest and for five potential house-keeping genes
including 18S rRNA, Gapdh, glucuronidase beta (Gusb),
hypoxanthine guanine phospho-ribosyl-transferase (Hprt1)
and peptidyl-prolyl isomerase A (Ppia). Each assay con-
sisted of a FAM dye-labeled TaqMan MGB probe and two
PCR primers. Every assay had been optimized by the man-
ufacturer to run under universal thermal cycling condi-
tions with a final reaction concentration of 250 nM for the
probe and 900 nM for each primer. Reverse transcription
and real-time PCR were run as described earlier [20]. Real-
Time StatMiner (Integromics, Granada, Spain) software
and relative quantification against calibrator samples
(ΔΔCt) were used for analysis of Applied Biosystems Taq-
Man gene expression assays. Five house-keeping genes
were applied on the TLDA card as potential internal con-
trols. To find the most stable endogenous controls, the
nonfinder stability scoring method [34] was used. A com-
puted internal control corresponding to the geometric
mean of Ct values of Gapdh, Hprt1 and Ppia was used for
subsequent ΔCt calculation [35]. Relative quantity (RQ)
represents the expression of a given gene in response to a
treatment compared to basal (control) expression.
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Figure 1 The effects of estrogen replacements on uterus weight (A) and body weight (B). E2 and ERa agonist 16a-lactone-estradiol (LE2)
changed the uterus weight significantly (p values for E2 and LE2 were p = 0.0001 in both cases), while DPN had no effect. In a similar way, E2
and LE2 decreased body weight significantly (p values for E2 and LE2 were p = 0.0035 and p = 0.0001, respectively). Change in body weight
represents the weight difference between the weight of the animal before and after the chronic treatment. Asterisks mark statistically significant
changes compared to vehicle. Error bars correspond to standard deviations.
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Expression profiling revealed numerous ERa agonist-
regulated immunity genes in the middle-aged female
neocortex
Oligonucleotide microarrays were used to study the effects
of the selective ERa agonist 16a-LE2 on the cortical gene
expression profile of middle-aged, ovariectomized rats.
Differences between the cortical transcriptomes of vehicle-
and ERa agonist-treated animals were evaluated, and the
top100 ERa agonist-regulated probe sets, i.e. probe sets
with the highest absolute fold change, were identified. The
100 probe sets encoded 87 ERa agonist-responsive genes,
which were categorized based on function (Figure 2). A
characteristic feature of the gene list was the high propor-
tion (24%) of genes related to immunity/inflammation.
Transcriptional regulation of the 21 immunity genes
included down-regulation of complement C3 and Serp-
ing1, MHC genes (Cd74, RT1-Aw2, RT1-N1), Fcgr2b, and
up-regulation of antimicrobial peptide (RatNP-3b, Np4,
Defa, Camp) and S100 protein genes (S100a9, S100a8), Ig
chains (IgG2a, Igh-1a, Igj, Igha), mast cell proteases
(Mcpt9, Mcpt8), Fcnb, Prg2 and Lrrc8a (Table 1).
Eighteen immunity genes were selected to confirm the
changes in their expression after ERa agonist treatment
by quantitative real-time PCR. All transcriptional
changes were confirmed (Table 1). The results provided
proof for the profound transcriptional regulation of
immunity/inflammation genes by 16a-LE2.
Pathway analysis supported the potent immunomodu-
latory effects of 16a-LE2 in the aging cortex. The list of
the top 20 pathways contained eight immunity-related
KEGG pathways including graft-versus-host disease,
autoimmune thyroid disease, allograft rejection, hemato-
poietic cell lineage, C and coagulation cascades,
cytokine-cytokine receptor interaction, systemic lupus
erythematosus and Jak-STAT signaling pathway
(Table 2).
Examination of the estrogenic regulation of
neuroinflammatory genes
Next, we selected genes involved in the recognition of
danger- and pathogen-associated signals, phagocytosis,
neuron-microglia communication and immunoregulation.
Although some genes were expressed in both neurons and
glia, most of the selected genes were predominantly
expressed in glial cells, several of them were specific for
microglia. We examined the effects of E2, 16a-LE2 and
ERb agonist DPN on the transcription of these genes.
Genes regulated by E2
We identified sixteen E2-dependent changes by quantita-
tive real-time PCR (Table 3). The E2-regulated genes
included defensin Np4 and RatNP-3b, S100 calcium bind-
ing protein gene S100a8, C3 and C4b, Ig chain IgG-2a,
lymphokines Ccl2, Il6 and Tgfb1, MHC gene RT1-Aw2,
macrophage expressed gene Mpeg1, ERa gene Esr1, pha-
gocytic receptors Fcgr2b and Itgam/Cd11b, and toll-like
receptors Tlr4 and Tlr9.
Neuroinflammatory genes regulated by both E2 and
isotype selective ER agonists
The isotype selective ER agonists also showed significant
transcriptional effects (Table 4). Among the E2-regulated
genes nine, including defensins, C3 and its receptor
Cd11b, IgG-2a, Ccl2, Il6, RT1-Aw2 and Fcgr2b were regu-
lated similarly by ERa and ERb agonists (Table 5). In addi-
tion, all the three ER agonists evoked up-regulation of
mast cell protease Mcpt8 and Mcpt9, and down-regulation
of Cd74 and IFN regulatory factor Irf7 (data not shown).
Genes regulated only by E2
We also found some compound-specific effects. Seven
genes, including C4b, Tgfb1, Mpeg1, Cx3cr1, Esr1, Tlr4
and Tlr9 were regulated only by E2 (Table 5).
Discussion
In this study, we identified the effects of ER agonists on
the transcription of neuroinflammatory genes in the fron-
tal cortex of middle-aged female rats. From the major
findings we conclude that 1) ERa agonist 16a-LE2 modu-
lates the expression of a large number of genes related to
immunity/inflammation, 2) E2, 16a-LE2 and DPN are
potent regulators of neuroinflammatory gene expression,
3) estrogens’ effects are mediated by both ERa and ERb,
4) estrogens target glial cells including microglia, 5) estro-
gens suppress genes encoding key elements of C-mediated
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Figure 2 Microarray analysis revealed 87 ERa agonist-
regulated genes which were categorized based on function.
ERa agonist-regulated genes included twenty-one immunity/
inflammation genes. The cluster contained S100 calcium-binding
(S100a9, S100a8) and defense proteins (RatNP-3b, Np4, Defa, Camp),
complement C3 and Serping1, Ig chains (Igha, IgG-2a, Igj), mast cell
proteases (Mcpt8, Mcpt9) and MHC antigens (RT1-Aw2, RT1-N1).
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can reverse age-related repression of ERa.
Expression profiling revealed potent immunomodulatory
effects of ERa agonist in the middle-aged female
neocortex
In the frontal cortex, ERa agonist 16a-LE2 regulated the
expression of numerous genes related to immunity/
inflammation. There were similarities between the
effects of 16a-LE2 and E2 [20] on immunity/inflamma-
tion gene expression. Overlapping effects include down-
regulation of C3, Cd74, Fcgr2b and RT1-Aw2. On the
other hand, a characteristic feature of the ERa agonist-
evoked changes was the up-regulation of genes encoding
antimicrobial peptides and S100 proteins. Antimicrobial
peptides represent evolutionary ancient weapons of the
immune system [36]. Antimicrobial activity of these
peptides contributes to the defense mechanism against
pathogens. Some of these peptides can chemoattract
monocytes and macrophages through CCR2 [37,38].
S100A8 and S100A9 calcium-binding proteins can form
a non-covalent heterocomplex which is involved in
diverse functions. In macrophages, the complex regu-
lates microtubule reorganization during phagocyte
migration [39], NADPH oxidase complex assembly and
calcium-dependent signaling during phagocyte activation
[40].
Our data indicate that 16a-LE2-induced up-regulation
of antimicrobial peptide and S100 protein genes may
support defense mechanisms associated with microglia,
astrocytes and blood-derived monocytes in the frontal
cortex of middle-aged females.
Estrogens are potent modulators of neuroinflammatory
gene expression
Profound regulation of immunity/inflammation genes by
16a-LE2 led us to further investigate the effects of
estrogens on additional neuroinflammatory genes of pri-
marily glial origin. We identified sixteen E2-regulated
changes including up-regulation of defensin Np4 and
RatNP-3b, IgG-2a, Il6 and Esr1, and down-regulation of
C3 and C4, lymphokine genes Ccl2 and Tgfb1, MHC
gene RT1-Aw2, Mpeg1, Cx3cr1, phagocytic and recogni-
tion receptor genes Fcgr2b, Itgam, Tlr4 and Tlr9. These
data indicate that decreasing levels of E2 result in a sig-
nificant change in the expression of neuroinflammatory
genes which alters the innate immune response in the
frontal cortex of aging females.
Table 1 Confirmation of the ERa agonist-regulated immunity/inflammation genes by quantitative real-time PCR
GENE MICROARRAY REAL-TIME PCR
Symbol Name probe set FC TaqMan ID RQ
S100a9 S100 calcium binding protein A9 1387125_at 3.655 Rn00585879_m1 2.029
S100a8 S100 calcium binding protein A8 1368494_at 3.458 Rn00587579_g1 2.558
RT1-Aw2 RT1 class Ib 1388202_at 0.291 Rn03034964_u1 0.658
RatNP-3b defensin ratNP-3 precursor 13700791_at 3.317 Rn01478511_gH 10.568
IgG-2a immonoglobulin G 1370394_at 3.204 Rn01429839_g1 9.257
Np4 defensin NP-4 precursor 1370470_at 3.031 Rn00597762_g1 2.268
Defa defensin, alpha 5, Paneth cell-specific 1387943_at 2.732 Rn02607254_g1 32.763
Prg2 proteoglycan 2 1387633_at 2.412 Rn00581137_m1 1.257
Camp cathelicidin antimicrobial peptide 1393603_at 2.297 Rn01446021_g1 1.521
Mcpt9 mast cell protease 9 1368501_s_at 2.235 Rn00755366_g1 5.825
Fcgr2b Fc fragment of IgG, receptor 1371079_at 0.451 Rn00598391_m1 0.649
Igh-1a immunoglobulin heavy chain 1388272_at 2.144
Cd74 CD74 1367679_at 0.473 Rn00565062_m1 0.685
Fcnb ficolin beta 1387378_at 2.071 Rn00586231_m1 1.922
Mcpt8 mast cell protease 8 1369586_at 2.056 Rn01789238_g1 3.784
Igj immunoglobulin joining chain 1383163_at 1.945 Rn01768305_m1 1.204
Igha immunoglobulin heavy chain, alpha 1371262_at 1.866
RT1-Aw2 RT1 class Ib 1388203_x_at 0.536 Rn03034964_u1 0.658
Serping1 C1-Inhibitor 1372254_at 0.559 Rn01485600_m1 0.690
C3 complement C3 1368000_at 0.559 Rn00566466_m1 0.743
RT1-N1 RT1 class Ib, locus N1 1387839_at 0.570 Rn00561858_m1 0.654
Lrrc8a leucine rich repeat containing 8 family 1382920_at 1.670
Transcriptional regulation of twenty-one immunity genes determined by the top100 probe sets of microarray analysis was confirmed by real-time PCR. FC, fold
change; RQ, relative quantity.
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to the effects of E2. All ER agonists evoked up-regula-
tion of defensin genes, Il6, and down-regulation of com-
plement C3 and some phagocytic receptors. Up-
regulation of defensins and down-regulation of C3 and
its receptor Cd11b can modulate various glial cell func-
tions. Up-regulation of Il6 can affect a broad range of
processes through the widely expressed IL6R in the cer-
ebral cortex [41].
Both ERa and ERb are involved in the
immunomodulatory effects of E2
The large number of overlapping genes indicated that
both ERa and ERb were involved in the remarkable
immunomodulatory effects ofE 2 .T h e s ef i n d i n g sa r ei n
accord with published results obtained in in vitro [42]
and in vivo [13,43] LPS and EAE [12] models.
The significant effect of DPN on neuroinflammatory
gene expression we found is in agreement with previous
results implicating ERb in the estrogenic regulation of
microglia-mediated inflammation [44]. Very recently, an
ERb-specific transrepression pathway has been identified
which is controlled endogenously with 5-androsten-
3b,17b-diol [45]. This mechanism inhibits inflammatory
responses of microglia and astrocytes [45]. These results
highlight the potential of selective ERb agonists to sup-
press microglia and astrocytes in various neuroinflam-
matory diseases [46].
E2 targets glial cells including microglia in the aging
frontal cortex
It is known that estrogens influence the regulatory func-
tions of microglia via ERs [13,44,47]. We found several
genes, such as Mpeg1 [48], Cx3cr1 [49], Cd11b [50], Tlr4
[51] and Tlr9 [52] which are expressed predominantly in
microglia, and were suppressed by E2. Down-regulation
of Cd11b is in accord with previous observations showing
suppression of microglia reactivity by estrogens [53,54]. It
is known that Cd11b expression correlates with microglia
reactivity, and accumulating evidence indicates that the
microglia phenotype changes during aging [4,55]. In the
aged CNS, microglial cells possess elevated reactivity as
characterized by up-regulation of cell surface activation
markers [55]. Our findings indicate that estrogens sup-
press microglia reactivity in the aging female cortex. This
is consistent with earlier observations that E2 attenuates
LPS-induced microglia reactivity in the rat brain [13].
Transcriptional regulation of the fractalkine and toll-like
receptors by E2 is novel finding and may have functional
consequences. As fractalkine receptor signaling is
Table 2 Pathway analysis using Tian’s method identified ERa agonist-regulated pathways related to immunity/
inflammation
rank pathway set size percent up average (NTk, NEk)
1 graft-versus-host disease 67 9 7.2
2 autoimmune thyroid disease 73 8 7.5
3 allograft rejection 68 9 7.8
4 cell adhesion molecules 189 18 8.0
5 retinol metabolism 64 11 9.5
6 type I diabetes mellitus 77 16 11.2
7 hematopoietic cell lineage 101 18 13.5
8 neuroactive ligand-receptor interaction 335 16 13.8
9 pantothenate and CoA biosynthesis 11 27 14.5
10 C and coagulation cascades 92 13 14.5
11 androgen and estrogen metabolism 33 15 16.5
12 Parkinson’s disease 139 69 16.5
13 cytokine-cytokine receptor interaction 210 23 20.5
14 systemic lupus erythematosus 92 22 22.2
15 caffeine metabolism 10 10 25.5
16 metabolism of xenobiotics by cytochrome P450 48 15 26.2
17 ECM-receptor interaction 101 24 26.2
18 Jak-STAT signaling pathway 172 28 27.2
19 drug metabolism - other enzymes 38 24 27.5
20 basal cell carcinoma 68 21 29.0
The analysis identified eight immune-related KEGG pathways (in bold) regulated by selective ERa agonist 16a-LE2. In the analysis, KEGG pathways were used as
collaborator gene sets. Using the Tian’s method [31], the relationship between gene sets and treatment is quantified by two statistics (Tk and Ek) formulating the
two hypotheses: i) the gene in a gene set shows the same pattern of associations with the treatment compared with the rest of the genes, ii) the gene set does
not contain any genes whose expression levels are associated with the treatment, respectively. KEGG pathways were ranked by the mean of normalized statistics
(NTk and NEk). Set size is the number of genes, percent up is the number of up-regulated genes in the KEGG pathway. C, complement.
Sárvári et al. Journal of Neuroinflammation 2011, 8:82
http://www.jneuroinflammation.com/content/8/1/82
Page 6 of 10involved in the regulation of microglia neurotoxicity [56],
E2 may alter this microglia function via down-regulation
of Cx3cr1.
E2 may suppress complement-mediated phagocytosis
involved in synapse elimination
In the aging female cortex, we demonstrated down-reg-
ulation of C3 in the presence of estrogens. This finding
is in line with the presence of 3 ERE sequences in the
C3 promoter [57,58] and estrogenic regulation of C3 in
other tissues [59]. Up-regulation of early C components
has been reported recently in the aging mouse forebrain
[60]. Following activation, C promotes local inflamma-
tion and facilitates destruction through opsonization
and lysis [61]. Host tissue is protected from C lysis by
soluble and membrane-bound regulators, but cortical
neurons express low level of C inhibitors which makes
them susceptible to C-mediated damage [62]. As a result
of the activation of the classical C pathway, C3b frag-
ment is released from C3, which in turn binds to the
surfaces of microbes, apoptotic or injured cells to label
them for elimination by professional phagocytes [63]. In
the CNS, microglial cells recognize C3b or its proteoly-
tic fragments via multiple receptors including Cd11b/
Cd18, which leads to phagocytosis of the labeled sub-
stance. This C-mediated mechanism is responsible for
the elimination of weak or unwanted synapses in the
developing and the aging CNS [63,64]. It is likely that
both astrocytes and microglia are involved in this
synapse elimination mechanism [65] which is highly
relevant to the layer-specific loss of synapses in the
estrogen-deprived, aging female neocortex [66].
Our results indicate that the expression of C3 and its
receptor Cd11b, and the reactivity of microglial cells are
suppressed by estrogens which may contribute to their
neuroprotective effects in the cerebral cortex [12,67-69].
Estrogens may alter the lymphokine profile
We also followed the effects of estrogens on the expres-
sion of Ccl2 and Il6. We found down-regulation of Ccl2
by ER agonists which was in agreement with recent data
observed in EAE model [70]. On the other hand, we
demonstrated up-regulation of Il6 in the frontal cortex of
middle-aged rats by E2 and isotype selective ER agonists.
This is in line with publications reporting estrogen-
responsiveness of Il6 [71]. However, Il6 shows down-
regulation by E2 in osteoblastoma Saos-2 cells [72], in
contrast to the up-regulation we report in the frontal cor-
tex. Different regulation of Il6 in human osteoblastoma
and rodent glial or neuronal cells can be a result of tis-
sue- and species-specificity of estrogen effects [73]. A
recent publication reports antimicrobial peptide-induced
IL6 expression in glial cells via P2Y receptor signaling
[74]. This finding suggests that secondary effects may be
involved in the transcriptional regulation of Il6 in a
chronic treatment paradigm.
In the CNS, the actions of IL6 are complex and
diverse that are mediated by the widely expressed IL6R
[41]. IL6 regulates neuroimmune and inflammatory
responses [75], neurogenesis [76], neuronal differentia-
tion, growth and survival [77]. As astrocytes are one of
the major sources of chemokines and cytokines in the
CNS, astrocytes are likely to contribute to the anti-
inflammatory effects of estrogens [69,70].
E2 can reverse age-related repression of ERa transcription
E2 replacement evoked up-regulation of ERa.T h i sf i n d -
ing suggested that chronic treatment with E2 supported
estrogen responsiveness of the cortex. It warrants com-
prehensive examination of the effects of estrogen replace-
ment in various tissues to correctly estimate the benefits
and risks of replacement therapies. Up-regulation of ERa
Table 3 Real-time PCR revealed that E2 regulated the
transcription of neuroinflammatory genes in the frontal
cortex of middle-aged female rats
Symbol Gene name TaqMan ID RQ
(E2)
p
complement
C3 complement C3 Rn00566466_m1 0.70 0.02
C4b complement C4 Rn00709527_m1 0.67 0.07
defensin
Np4 defensin NP-4 precursor Rn00597762_g1 2.56 0.08
RatNP-
3b
defensin ratNP-3 precursor Rn01478511_gH 13.27 0.06
Ig chain
IgG-2a immonoglobulin G Rn01429839_g1 8.23 0.10
lymphokine
Ccl2 chemokine (C-C) ligand 2 Rn00580555_m1 0.52 0.06
Il6 interleukin-6 Rn00561420_m1 2.82 0.04
Tgfb1 transforming growth factor
beta 1
Rn00572010_m1 0.78 0.01
MHC
RT1-
Aw2
RT1 class Ib Rn03034964_u1 0.61 0.10
miscellaneous
Cx3cr1 fractalkine receptor Rn00591798_m1 0.82 0.04
Mpeg1 macrophage expressed gene
1
Rn02769865_s1 0.61 0.01
nuclear receptor
Esr1 estrogen receptor-a Rn00562166_m1 1.39 0.05
phagocytic receptor
Fcgr2b Fc fragment of IgG, receptor Rn00598391_m1 0.61 0.03
Itgam CD11b Rn00709342_m1 0.57 0.01
Toll-like receptor
Tlr4 Toll-like receptor 4 Rn00569848_m1 0.81 0.05
Tlr9 Toll-like receptor 9 Rn01640054_m1 0.74 0.07
Relative quantities were the mean of six individual samples. One-way ANOVA
was used to evaluate statistical significance. RQ, relative quantity.
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during aging [78], and it might support the hypothesis of
‘critical period’ to start an effective hormone replacement
in postmenopausal women [79].
Conclusion
This study provided evidence that E2 and isotype selec-
tive ER agonists modulate the expression of neuroinflam-
matory genes in the middle-aged female frontal cortex.
Our results suggest that aging and decreasing level of E2
together result in significant alterations of the innate
immune response rendering the middle-aged female
brain susceptible for inflammation. The use of ERa ago-
nist therapy in postmenopausal women is hampered by
the mammotrophic and uterotrophic activities of ERa
agonists. As ERb agonists have only minor effects in clas-
sic estrogen target tissues, we propose that ERb is a pro-
mising drug target to suppress the glial cell response in
the E2-deprived female brain and in various neuroinflam-
matory diseases.
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neuroinflammatory genes
Symbol Gene name TaqMan ID RQ(LE2) RQ(DPN)
Complement
C3 complement C3 Rn00566466_m1 0.743 0.801
Defensin
Np4 defensin NP-4 precursor Rn00597762_g1 2.268 2.578
RatNP-3b defensin ratNP-3 precursor Rn01478511_gH 10.568 4.574
Ig chain
IgG-2a immonoglobulin G Rn01429839_g1 9.257 4.048
Lymphokine
Ccl2 chemokine (C-C) ligand 2 Rn00580555_m1 0.824 0.703
Il6 interleukin-6 Rn00561420_m1 2.232 2.635
MHC
RT1-Aw2 RT1 class Ib Rn03034964_u1 0.658 0.463
phagocytic receptor
Fcgr2b Fc fragment of IgG, receptor Rn00598391_m1 0.649 0.651
Itgam CD11b Rn00709342_m1 0.655 0.798
Nine genes were regulated in a similar way by selective ERa and ERb agonists indicating that both ERs were involved in the transcriptional regulation of these
genes. Relative quantities were the mean of six individual samples. RQ, relative quantity; LE2, 16a-LE2; DPN, diarylpropionitrile.
Table 5 Summary of estrogenic regulation of
neuroinflammatory genes
Symbol Gene name RQ
(E2)
RQ
(LE2)
RQ
(DPN)
Analogous changes
C3 complement C3 0.703 0.743 0.801
Ccl2 chemokine (C-C) ligand 2 0.527 0.824 0.703
Fcgr2b Fc fragment of IgG, receptor 0.615 0.649 0.651
IgG-2a Ig chain 8.228 9.257 4.048
Il6 interleukin-6 2.823 2.232 2.635
Itgam CD11b 0.571 0.655 0.798
Np4 defensin NP-4 precursor 2.562 2.268 2.578
RatNP-
3b
defensin ratNP-3 precursor 13.266 10.568 4.574
RT1-Aw2 RT1 class Ib 0.606 0.658 0.463
E2-specific changes
C4b C4 0.670 0.881 0.785
Cx3cr1 fractalkine receptor 0.820 0.914 1.041
Esr1 estrogen receptor-a 1.392 1.169 0.908
Mpeg1 macrophage expressed gene 1 0.611 0.978 0.869
Tgfb1 transforming growth factor beta
1
0.779 0.921 0.938
Tlr4 Toll-like receptor 4 0.810 0.993 1.069
Tlr9 Toll-like receptor 9 0.737 0.896 0.845
The effects of isotype selective ER agonists on the transcription of E2-
regulated genes revealed two groups: analogous and specific changes. The
large number of analogous changes (genes which are regulated similarly by
the three ER agonists) revealed that both ERa and ERb were involved in the
transcriptional regulation of neuroinflammatory genes.
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